marijuana stocks

Pure Global launches e-store at PureSinse.com to begin serving cannabis patients from across Canada

Pure Global Cannabis Inc. (TSX.V:PURE;OTC: PRCNF; FRA:1QS) (the “Company” or “Pure Global”) an integrated, growth-oriented life sciences and cannabis consumer products company, through its operating subsidiary PureSinse Inc. (“PureSinse”), is announcing the launch of its e-store at PureSinse.com, subsequent to receiving its Sales License from Health Canada on January 11, 2019 . The online store is ready to service physicians and register medical cannabis patients from across Canada who hold a valid medical document. Once registered, patients can purchase quality tested premium legal cannabis products from PureSinse for secure discreet courier delivery.

“We are excited to open our PureSinse e-store and start servicing the medical community which we feel his hugely underserviced,” said Malay Panchal, President and CEO of Pure Global. “Our site is robust, user-friendly, easy to navigate, and we have many patients already pre-registered. It offers an optimal user experience, with enhancements to follow that will offer more education and clinical material. This is the start of revenue generation for the company as we strive towards servicing thousands of patients by year end,” added Mr. Panchal.

As a Health Canada approved licensed producer, PureSinse will continue to add quality cannabis products to the eStore as they become available. Currently the company is licensed to sell dried flower and will be adding oils and oil derivative products upon receiving further Health Canada approvals. PureSinse products are made with sustainable and recyclable packaging, and strive to adopt sustainable methods throughout its production, processing, operating, and packaging methodology. Registered patients will receive expedited delivery and free home shipping for purchases over $100 CAD.

PureSinse invites patients to register at PureSinse.com by completing the webform then submitting a valid medical document. For patients that do not have a medical document, PureSinse Care Team can provide guidance on how to obtain a medical document within minutes through telemedicine. Once registered patients have full access to the eStore to place orders.

Physicians who are looking for a dependable trusted medical cannabis brand built by healthcare professionals for the medical community, can send their patients to PureSinse. Physicians can register then download a blank medical document from our site for their patient which can then be submitted electronically, by fax, or by mail for expedited processing for the patient.

About Pure Global Cannabis

Pure Global Cannabis Inc. (TSX.V:PURE; OTC:PRCNF; FRA:1QS) is an innovation-based cannabis Company led by experienced pharma, biotechnology, horticultural, consumer packaged goods (CPG), and supply chain experts. The Company’s wholly owned subsidiary, PureSinse Inc., is a licensed producer under the Cannabis Act, 2017. The Company’s Brampton campus houses facilities for vertically farmed cultivation, R&D, extraction, manufacturing, and distribution. PURE will produce branded and white-labeled cannabis products for the medical, pharmaceutical, wellness, health & beauty, natural health, food & beverage, and recreational legal markets with uniquely formulated and purified concentrates. The Company is using the Canadian market as a springboard to develop and manufacture GMP-compliant cannabis products for international sale and distribution with a goal to become one of the most trusted premium international cannabis brands.

FORWARD-LOOKING STATEMENTS
This news release contains certain forward-looking statements, including, but not limited to, statements about Pure Global’s future plans and intentions.  Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, Pure Global cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release, and Pure Global assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

To register to Pure Global’s mailing list, please visit www.pureglobal.com. Follow @pureglobalcanna on Twitter and Facebook and @pureglobalcannabis on Instagram.

SOURCE Pure Global Cannabis Inc.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Village Farms International (VFF) Reports Strong Second Quarter 2019 Results

Village Farms International Reports Strong Second Quarter 2019 Results – Canadian Cannabis…

Trulieve Cannabis Corp. (TCNNF) Reports Results of 2022 Annual Meeting of Shareholders

Trulieve Reports Results of 2022 Annual Meeting of Shareholders Trulieve Cannabis Corp.…

GT Biopharma, Inc. (GTBP) Announces FDA Notification of Commencement of Enrollment in Human GTB-3550 Trike™ Phase i/ii Clinical Trial

GT Biopharma Announces FDA Notification of Commencement of Enrollment in Human GTB-3550…

$ENRT Form 8-K

Form 8-K for ENERTOPIA CORP. 30-Jan-2015 Unregistered Sale of Equity Securities, Regulation…